Concerns about ARIA and the associated monitoring requirements for Leqembi could present significant barriers to uptake. EXTON, Pa., April 5, 2023 /PRNewswire/ — With the accelerated approval on January 6, 2023 for early Alzheimer’s disease, Eisai/Biogen’s Leqembi (lecanemab-irmb) became…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.